drugset / Trial / NCT06462794
First In Human Study of CX-801 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
Timeline
- Start
- 2024-08-28
- Primary completion
- 2028-02-28
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CX-801 | Unknown | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |